<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Clobazam monotherapy for focal or generalized seizures - Arya, R - 2018 | Cochrane Library</title> <meta content="Clobazam monotherapy for focal or generalized seizures - Arya, R - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009258.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Clobazam monotherapy for focal or generalized seizures - Arya, R - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009258.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009258.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Clobazam monotherapy for focal or generalized seizures" name="citation_title"/> <meta content="Ravindra Arya" name="citation_author"/> <meta content="Cincinnati Children's Hospital Medical Center" name="citation_author_institution"/> <meta content="ravindra.arya4@gmail.com" name="citation_author_email"/> <meta content="Nisha Giridharan" name="citation_author"/> <meta content="University of Cincinnati" name="citation_author_institution"/> <meta content="Vidhu Anand" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Sushil K Garg" name="citation_author"/> <meta content="Mayo Clinic College of Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009258.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/07/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009258.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009258.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009258.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [*therapeutic use]; Benzodiazepines [*therapeutic use]; Carbamazepine [therapeutic use]; Clobazam; Epilepsies, Partial [*drug therapy]; Epilepsy, Generalized [*drug therapy]; Phenytoin [therapeutic use]; Randomized Controlled Trials as Topic; Seizures [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009258.pub3&amp;doi=10.1002/14651858.CD009258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="xNbeAU8n";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009258\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009258\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009258.pub3",title:"Clobazam monotherapy for focal or generalized seizures",firstPublishedDate:"Jul 11, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009258.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009258.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009258.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009258.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009258.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009258.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009258.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009258.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009258.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009258.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1941 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009258.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/appendices#CD009258-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/table_n/CD009258StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/table_n/CD009258StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Clobazam monotherapy for focal or generalized seizures</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information#CD009258-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ravindra Arya</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information#CD009258-cr-0003">Nisha Giridharan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information#CD009258-cr-0004">Vidhu Anand</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information#CD009258-cr-0005">Sushil K Garg</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information/en#CD009258-sec-0100">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 July 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009258.pub3">https://doi.org/10.1002/14651858.CD009258.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009258-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009258-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009258-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009258-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009258-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009258-abs-0001" lang="en"> <section id="CD009258-sec-0001"> <h3 class="title" id="CD009258-sec-0001">Background</h3> <p>This is an updated version of the original Cochrane Review published in Issue 10, 2014. There is a need to expand monotherapy options available to a clinician for the treatment of new focal or generalized seizures. A Cochrane systematic review for clobazam monotherapy is expected to define its place in the treatment of new‐onset or untreated seizures and highlight gaps in evidence. </p> </section> <section id="CD009258-sec-0002"> <h3 class="title" id="CD009258-sec-0002">Objectives</h3> <p>To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new‐onset focal or generalized seizures. </p> </section> <section id="CD009258-sec-0003"> <h3 class="title" id="CD009258-sec-0003">Search methods</h3> <p>For the latest update we searched the following databases on 19 March 2018: the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid, 1946‐ ), BIOSIS Previews (1969‐ ), <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, and the <a href="http://apps.who.int/trialsearch/" target="_blank">World Health Organization International Clinical Trials Registry Platform</a> (ICTRP). There were no language restrictions. </p> </section> <section id="CD009258-sec-0004"> <h3 class="title" id="CD009258-sec-0004">Selection criteria</h3> <p>Randomized or quasi‐randomized controlled trials comparing clobazam monotherapy versus placebo or other anti‐seizure medication in people with two or more unprovoked seizures or single acute symptomatic seizure requiring short‐term continuous anti‐seizure medication, were eligible for inclusion. </p> </section> <section id="CD009258-sec-0005"> <h3 class="title" id="CD009258-sec-0005">Data collection and analysis</h3> <p>Primary outcome measure was time on allocated treatment (retention time), reflecting both efficacy and tolerability. Secondary outcomes included short‐ and long‐term effectiveness measures, tolerability, quality of life, and tolerance measures. Two authors independently extracted the data. </p> </section> <section id="CD009258-sec-0006"> <h3 class="title" id="CD009258-sec-0006">Main results</h3> <p>We identified three trials fulfilling the review criteria, which included 206 participants. None of the identified studies reported the preselected primary outcome measure. A meta‐analysis was not possible. Lack of detail regarding allocation concealment and a high risk of performance and detection bias in two studies prompted us to downgrade the quality of evidence (by using the GRADE approach) for some of our results due to risk of bias. </p> <p>Regarding retention at 12 months, we detected no evidence of a statistically significant difference between clobazam and carbamazepine (risk ratio (RR) 0.83, 95% confidence interval (CI) 0.61 to 1.12; low‐quality evidence). There was low‐quality evidence that clobazam led to better retention compared with phenytoin (RR 1.43, 95% CI 1.08 to 1.90). We could not determine whether participants receiving clobazam were found to be less likely to discontinue it due to adverse effects as compared to phenytoin (RR 0.10, 95% CI 0.01 to 1.65, low‐quality evidence). </p> </section> <section id="CD009258-sec-0007"> <h3 class="title" id="CD009258-sec-0007">Authors' conclusions</h3> <p>We found no advantage for clobazam over carbamazepine for retention at 12 months in drug‐naive children and a slight advantage of clobazam over phenytoin for retention at six months in adolescents and adults with neurocysticercosis in a single clinical trial each. At present, the available evidence is insufficient to inform clinical practice. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009258-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009258-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009258-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009258-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009258-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009258-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009258-abs-0003" lang="en"> <h3>Clobazam monotherapy for focal or generalized seizures</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence for clobazam monotherapy for the treatment of new‐onset or untreated focal or generalized seizures. </p> <p><b>Background</b> </p> <p>Epilepsy is characterized by an abnormal propensity for the brain to have seizures, which are discrete episodes of abnormal neuronal electrical activity. Seizures may arise from a particular part (focal seizures) or whole of the brain at once (generalized seizures). In this review we assessed clobazam as monotherapy (single‐drug treatment) for new‐onset or untreated focal or generalized onset seizures. </p> <p><b>Study characteristics</b> </p> <p>Our searches identified three studies of low quality comparing clobazam with carbamazepine and phenytoin for monotherapy of seizures. They included a multi‐center study that compared the effectiveness of clobazam and carbamazepine monotherapy in 115 children with untreated epilepsy; a single‐center study comparing clobazam with phenytoin in 48 adolescents and adults with neurocysticercosis; and a single‐center study comparing clobazam with carbamazepine monotherapy in 43 children with benign childhood epilepsy with centrotemporal spikes (BCECTS). In clinical trials with anti‐seizure medications, effectiveness is conventionally measured by the time a person remains on the allocated treatment, which reflects that the person will stop taking medicine either if it is ineffective or if there are unacceptable adverse effects. </p> <p><b>Key results</b> </p> <p>No significant advantage of clobazam over carbamazepine in people with previously untreated focal or generalized seizures was seen for retention at 12 months. A slight advantage of clobazam over phenytoin for retention at six months was noted in one study, which was limited to participants having seizures due to neurocysticercosis. No significant differences in proportion of BCECTS participants who achieved seizure freedom at four weeks, between four and 40 weeks, and during the last nine months of treatment between clobazam and carbamazepine were found. Also, no significant difference in the proportion of participants who achieved a 50% or greater reduction in their seizures at four weeks on clobazam versus carbamazepine was noted. However, participants randomized to clobazam achieved seizure control sooner than those treated with carbamazepine. </p> <p>None of the studies measured the amount of time that participants remained on allocated treatment (retention time), or quality of life. We did assess data from the studies regarding the number of participants who remained on treatment at specific time points. However, we were unable to determine whether people with previously untreated focal or generalized seizures receiving clobazam were more likely to remain on treatment at 12 months than those given carbamazepine due to low numbers of participants in the study. One of the studies showed that social and academic outcomes improved in participants taking clobazam as well as carbamazepine; however, there was no comparative analysis. </p> <p><b>Quality of evidence</b> </p> <p>At present, there is insufficient evidence to inform clinical practice regarding clobazam monotherapy in focal or generalized seizures. The quality of evidence for the outcomes was also affected by design issues and low sample‐size. There is a definite need for well‐designed, adequately powered, randomized controlled trials of clobazam monotherapy in people with new‐onset/untreated seizures. </p> <p>The evidence is current to March 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009258-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009258-sec-0084"></div> <h3 class="title" id="CD009258-sec-0085">Implications for practice</h3> <section id="CD009258-sec-0085"> <p>This systematic review did not find sufficient evidence from randomized controlled trials to inform clinical practice meaningfully. </p> </section> <h3 class="title" id="CD009258-sec-0086">Implications for research</h3> <section id="CD009258-sec-0086"> <p>Conventionally, clobazam has been used as an add‐on therapy especially in children with Lennox‐Gastaut syndrome and other difficult‐to‐treat epilepsies. Certain evidence gaps must be addressed to better define the role of clobazam as monotherapy in people with epilepsy. </p> <p> <ul id="CD009258-list-0019"> <li> <p>There is a need for double‐blind randomized controlled trials comparing clobazam with other anti‐seizure drugs. These clinical trials must fulfil the criteria for class I studies as described in the recent update by International League Against Epilepsy (ILAE) (<a href="./references#CD009258-bbs2-0027" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , GuerreiroC , KalviainenR , et al. for the ILAE subcommission of AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2013;54(3):551‐63. [PUBMED: 23350722] ">Glauser 2013</a>). These prospective, randomized, controlled, clinical trials should be carried out in several representative patient samples with a primary outcome of efficacy or effectiveness and double‐blind treatment duration of at least 48 weeks without any forced study‐exit criteria. Either clobazam should have clear superiority over an adequate comparator, or a failed superiority study or non‐inferiority study should be analyzed in accordance with the criteria provided in the ILAE update (<a href="./references#CD009258-bbs2-0027" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , GuerreiroC , KalviainenR , et al. for the ILAE subcommission of AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2013;54(3):551‐63. [PUBMED: 23350722] ">Glauser 2013</a>). </p> </li> <li> <p>As evidence becomes available for other drugs to be considered as acceptable monotherapies for focal or generalized seizures in clinical practice and as adequate comparators for clinical trials, studies should be designed to compare clobazam with these. </p> </li> <li> <p>A sufficient sample size should be estimated to have adequate power to conduct subgroup analysis for different age groups and seizure types, and to compare adverse effect frequencies. </p> </li> <li> <p>Future studies should include tolerability measures (treatment‐emergent adverse events), quality of life measures, and, tolerance measures. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009258-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009258-sec-0022"></div> <div class="table" id="CD009258-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Clobazam versus carbamazepine for focal or generalized seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clobazam versus carbamazepine for focal or generalized seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with focal or generalized seizures<br/> <b>Settings:</b> 15 Canadian pediatric epilepsy centers (<a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a>); single center, outpatient clinic from Cuba (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>)<br/> <b>Intervention:</b> clobazam versus carbamazepine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Clobazam </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time on allocated treatment (retention time)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Retention at 12 months</b><br/> Follow‐up: mean 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.83</b> (0.61 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>115<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>543 per 1000</b> (399 to 732) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure freedom at 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>720 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>611 per 1000</b> (396 to 950) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.85</b> (0.55 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>low</b><sup>2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure freedom 4‐40 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>760 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>722 per 1000</b> (502 to 1034) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.95</b> (0.66 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>low</b><sup>2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50% responder rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>944 per 1000</b> (752 to 1184) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.18</b> (0.94 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>low</b><sup>2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects requiring withdrawal/discontinuation of study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Blinding of participants and personnel was not done in this open‐label study. This can potentially affect assessment of this outcome. Downgraded by 1.<br/> <sup>2</sup>Only 1 study, hence no 'inconsistency' and no 'publication bias'.<br/> <sup>3</sup>Wide CI, downgraded by 1. </p> <p><sup>4</sup>Allocation concealment not stated, which could potentially introduce selection bias. Blinding of participants and personnel was not done in this open‐label study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009258-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Clobazam versus phenytoin for focal or generalized seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clobazam versus phenytoin for focal or generalized seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma </p> <p><b>Settings:</b> single Indian teaching hospital </p> <p><b>Intervention:</b> clobazam </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Clobazam versus phenytoin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time on allocated treatment (retention time)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Retention at 6 months</b> (measured by the number of treatment failures in each group, which was defined as either breakthrough seizure or adverse effects requiring discontinuation or dose modification of study medication)<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>RR 1.43</b> <br/> (1.08 to 1.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>48<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>953 per 1000</b> (720 to 1267) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure freedom at 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure freedom 4‐40 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50% responder rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects requiring withdrawal/discontinuation of study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.10</b> <br/> (0.01 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>48<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/> (2 to 367) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Allocation concealment not stated, which could potentially introduce selection bias. Blinding of participants and personnel was not done in this open‐label study. This can potentially affect assessment of 'adverse effects requiring withdrawal' and hence 'retention time'. Downgraded by 1.<br/> <sup>2</sup>Only 1 study, thus no 'inconsistency' and no 'publication bias'.<br/> <sup>3</sup>Wide confidence interval and small sample size. Downgraded by 1. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009258-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009258-sec-0023"></div> <p>This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (<a href="./references#CD009258-bbs2-0042" title="AryaR , AnandV , GargSK , MichaelBD . Clobazam monotherapy for partial‐onset or generalized‐onset seizures. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD009258.pub2] ">Arya 2014</a>). </p> <section id="CD009258-sec-0024"> <h3 class="title" id="CD009258-sec-0024">Description of the condition</h3> <p>Epilepsy is one of the most common disorders of the brain (<a href="./references#CD009258-bbs2-0024" title="EngelJJr , PedleyTA . Introduction: What is Epilepsy?. In: EngelJJr , PedleyTA editor(s). Epilepsy. A Comprehensive Textbook. 2nd Edition. Vol. 1, Philadelphia: Lippincott Williams &amp; Wilkins, 2008:1‐7. ">Engel 2008</a>). It accounts for 1% of the global burden of disease, a figure equivalent to breast cancer in women and lung cancer in men (<a href="./references#CD009258-bbs2-0034" title="MurrayCGL , LopezAD . Global comparative assessment in the Health Sector; Disease Burden, Expenditures, and Intervention Packages. Geneva: WHO, 1994. ">Murray 1994</a>). </p> <p>An epileptic seizure is defined as a transient occurrence of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain (<a href="./references#CD009258-bbs2-0025" title="FisherRS , VanEmde BoasW , BlumeW , ElgerC , GentonP , LeeP , et al. Epileptic seizures and epilepsy. Definitions proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia2005;46(4):470‐2. ">Fisher 2005</a>). Sometimes, a seizure can be a natural response of the normal brain to transient disturbances in function. Such seizures are referred to as provoked or acute symptomatic seizures. Epilepsy is a chronic condition of the brain characterized by an enduring propensity to generate epileptic seizures, and by the neurobiological, cognitive, psychological, and social consequences of this condition (<a href="./references#CD009258-bbs2-0025" title="FisherRS , VanEmde BoasW , BlumeW , ElgerC , GentonP , LeeP , et al. Epileptic seizures and epilepsy. Definitions proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia2005;46(4):470‐2. ">Fisher 2005</a>). </p> <p>Worldwide, epilepsy affects 50 million people (<a href="./references#CD009258-bbs2-0024" title="EngelJJr , PedleyTA . Introduction: What is Epilepsy?. In: EngelJJr , PedleyTA editor(s). Epilepsy. A Comprehensive Textbook. 2nd Edition. Vol. 1, Philadelphia: Lippincott Williams &amp; Wilkins, 2008:1‐7. ">Engel 2008</a>). In high‐income countries, the age‐adjusted incidence of epilepsy ranges from 24 to 53 per 100,000 person‐years (<a href="./references#CD009258-bbs2-0018" title="BanerjeePN , HauserWA . Incidence and Prevalence. In: Engel JrJ , PedleyTA editor(s). Epilepsy. A Comprehensive Textbook. 2nd Edition. Vol. 1, Philadelphia: Lippincott Williams &amp; Wilkins, 2008:45‐56. ">Banerjee 2008</a>). Total population studies reporting the incidence of a first diagnosis of unprovoked seizures provide estimates of incidence ranging from 26 to 70 per 100,000 person‐years (<a href="./references#CD009258-bbs2-0018" title="BanerjeePN , HauserWA . Incidence and Prevalence. In: Engel JrJ , PedleyTA editor(s). Epilepsy. A Comprehensive Textbook. 2nd Edition. Vol. 1, Philadelphia: Lippincott Williams &amp; Wilkins, 2008:45‐56. ">Banerjee 2008</a>). It is likely that the incidence of epilepsy may be higher in low‐ and middle‐income countries than in high‐income countries, due to increased occurrence of perinatal insults and neuro‐infections. </p> </section> <section id="CD009258-sec-0025"> <h3 class="title" id="CD009258-sec-0025">Description of the intervention</h3> <p>Clobazam is a benzodiazepine anti‐seizure medication. It has been shown to be an effective anticonvulsant for monotherapy of previously untreated children with focal seizures, with a similar efficacy to phenytoin or carbamazepine. Clobazam is also efficacious when used as an add‐on treatment for refractory focal epilepsy in children and adults (<a href="./references#CD009258-bbs2-0012" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. [PUBMED: 3115770] ">Koeppen 1987</a>; <a href="./references#CD009258-bbs2-0038" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy. A controlled trial. Archives of Neurology1986;43(8):824‐6. ">Schmidt 1986</a>), and intermittent clobazam therapy may be useful for the treatment of febrile seizures (<a href="./references#CD009258-bbs2-0014" title="RoseW , KirubakaranC , ScottJX . Intermittent clobazam therapy in febrile seizures. Indian Journal of Pediatrics2005;72(1):31‐3. [PUBMED: 15684445] ">Rose 2005</a>). The Canadian Clobazam Cooperative Group performed the largest single study, comprising 877 participants with epilepsy, both children and adults, with multiple types of seizures including atypical absence, myoclonic seizures, Lennox‐Gastaut syndrome, and generalized tonic‐clonic seizures (<a href="./references#CD009258-bbs2-0020" title="Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia1991;32(3):407‐16. ">Canadian Clobazam Cooperative Group 1991</a>). More than half the participants became seizure free or had a greater than 50% reduction in seizure frequency. Clobazam is thought to have fewer side effects than other benzodiazepines at equipotent doses (<a href="./references#CD009258-bbs2-0039" title="SchmidtD , WilenskyAJ . Benzodiazepines. In: EngelJJr , PedleyTA editor(s). Epilepsy. A Comprehensive Textbook. 2nd Edition. Vol. 2, Philadelphia: Lippincott Williams &amp; Wilkins, 2008:1531‐41. ">Schmidt 2008</a>), although development of tolerance in 30% to 50% of people is an important disadvantage. </p> <p>Clobazam is metabolized by hepatic microsomal enzymes. The main active metabolite is desmethylclobazam, also called norclobazam. Clobazam and its metabolite are slowly eliminated with a half‐life of 20 to 56 hours. Although it is only one‐fifth as potent as the parent compound, because the ratio of plasma levels of desmethylclobazam to those of the parent drug is about 10:1, and because the metabolite also has a longer half‐life, the anticonvulsant property may be more attributable to desmethylclobazam than to clobazam (<a href="./references#CD009258-bbs2-0039" title="SchmidtD , WilenskyAJ . Benzodiazepines. In: EngelJJr , PedleyTA editor(s). Epilepsy. A Comprehensive Textbook. 2nd Edition. Vol. 2, Philadelphia: Lippincott Williams &amp; Wilkins, 2008:1531‐41. ">Schmidt 2008</a>). </p> </section> <section id="CD009258-sec-0026"> <h3 class="title" id="CD009258-sec-0026">How the intervention might work</h3> <p>Gamma amino butyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system. It binds to at least two classes of receptors, GABA‐A and GABA‐B, which are found on almost all cortical neurons (<a href="./references#CD009258-bbs2-0033" title="MacdonaldR . Benzodiazepines. Mechanism of Action. In: LevyR , MattsonR , MeldrumB , et al. editor(s). Antiepileptic Drugs. 5th Edition. Philadelphia: Lippincott, Williams &amp; Wilkins, 2002:179‐86. ">Macdonald 2002)</a>. Benzodiazepines act primarily as anticonvulsants by interacting with GABA‐A receptors at a specific binding site and allosterically modifying the receptor currents to enhance inhibition by increasing the frequency of receptor opening without significantly affecting the mean open time or conductance of the channel. It is now known that the GABA receptor is made up of many different subunits (α, β, γ, δ, ρ) with different subtypes in many combinations. GABA‐A receptors containing the α1 subunit are an important target for benzodiazepines (<a href="./references#CD009258-bbs2-0037" title="RogawskiMA , LöscherW . The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience2004;5(1):1‐12. ">Rogawski 2004</a>). </p> <p>The anti‐absence activity of benzodiazepines probably results from their ability to interfere with hypersynchronous activity in the thalamocortical circuitry. More specifically, benzodiazepines are thought to reduce the inhibitory output of the reticular neurons by effects on benzodiazepine‐sensitive α3‐containing GABA‐A receptors (<a href="./references#CD009258-bbs2-0037" title="RogawskiMA , LöscherW . The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience2004;5(1):1‐12. ">Rogawski 2004</a>). However, some of the clinical effects of benzodiazepines in experimental animals cannot be explained simply by their potentiation of GABA‐activated currents (<a href="./references#CD009258-bbs2-0039" title="SchmidtD , WilenskyAJ . Benzodiazepines. In: EngelJJr , PedleyTA editor(s). Epilepsy. A Comprehensive Textbook. 2nd Edition. Vol. 2, Philadelphia: Lippincott Williams &amp; Wilkins, 2008:1531‐41. ">Schmidt 2008</a>), and benzodiazepines may act on targets other than the GABA‐A receptor. Through unknown mechanisms, benzodiazepines may produce elevations of GABA levels in the cerebrospinal fluid (<a href="./references#CD009258-bbs2-0032" title="LöscherW , SchmidtD . Diazepam increases aminobutyric acid in human cerebrospinal fluid. Journal of Neurochemistry1987;49:152‐7. ">Löscher 1987</a>). At high concentrations, especially those that may be achieved in the treatment of status epilepticus, benzodiazepines may have significant effects on voltage‐gated sodium and, to a lesser extent, on calcium channels (<a href="./references#CD009258-bbs2-0039" title="SchmidtD , WilenskyAJ . Benzodiazepines. In: EngelJJr , PedleyTA editor(s). Epilepsy. A Comprehensive Textbook. 2nd Edition. Vol. 2, Philadelphia: Lippincott Williams &amp; Wilkins, 2008:1531‐41. ">Schmidt 2008</a>). </p> </section> <section id="CD009258-sec-0027"> <h3 class="title" id="CD009258-sec-0027">Why it is important to do this review</h3> <p>The antiepileptic drug (AED) choices for monotherapy of new‐onset or untreated seizures has a fairly limited evidence base. The updated International League Against Epilepsy monotherapy guidelines has identified Level A evidence, according to their criteria, for only carbamazepine, phenytoin, levetiracetam and zonisamide for focal seizures in adults, and for ethosuximide and valproate in childhood absence epilepsy (<a href="./references#CD009258-bbs2-0027" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , GuerreiroC , KalviainenR , et al. for the ILAE subcommission of AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2013;54(3):551‐63. [PUBMED: 23350722] ">Glauser 2013</a>). This rigorous update also highlighted the lack of well‐designed clinical trials and appropriate evidence for monotherapy of several other patient groups with new‐onset or untreated epilepsy, who are candidates for monotherapy with AEDs. </p> <p>Also, the majority of the conventional and some of the newer AEDs have important adverse effects in a significant proportion of people receiving them (<a href="./references#CD009258-bbs2-0035" title="PorterRJ , MeldrumBS . Antiseizure Drugs. In: KatzungBG editor(s). Basic and Clinical Pharmacology. 10th Edition. Mc Graw Hill, 2007:374‐94. ">Porter 2007)</a>, which precludes their use in certain patient groups. Hence, there is a continued need to assess the efficacy and safety of alternative newer AEDs for monotherapy of new‐onset or untreated epilepsy. A Cochrane Review of clobazam monotherapy would help to define its place in the monotherapy of new‐onset or untreated epilepsy and might help in increasing the number of available choices for treatment of these people. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009258-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009258-sec-0028"></div> <p>To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new‐onset focal or generalized seizures. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009258-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009258-sec-0029"></div> <section id="CD009258-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009258-sec-0031"> <h4 class="title">Types of studies</h4> <p> <ul id="CD009258-list-0001"> <li> <p>Randomized controlled trials (RCTs) and quasi‐randomized controlled trials (QRCTs).</p> </li> <li> <p>Studies may be double‐blinded, single‐blinded or unblinded.</p> </li> </ul> </p> </section> <section id="CD009258-sec-0032"> <h4 class="title">Types of participants</h4> <p> <ul id="CD009258-list-0002"> <li> <p>Adults and children aged more than six months with two or more unprovoked seizures or a single acute symptomatic seizure. </p> </li> </ul> </p> </section> <section id="CD009258-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD009258-list-0003"> <li> <p>Intervention: clobazam monotherapy for at least three months continuously.</p> </li> <li> <p>Comparator: placebo or any other anti‐seizure drug.</p> </li> </ul> </p> </section> <section id="CD009258-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD009258-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD009258-sec-0036"> <h6 class="title">Time on allocated treatment (retention time)</h6> <p>This is a combined outcome reflecting both efficacy and tolerability, as treatment may be withdrawn due to continued seizures, side effects or a combination of both. This is an outcome to which the participant makes a contribution, and is the primary outcome measure recommended by the Commission on Antiepileptic Drugs of the International League Against Epilepsy (<a href="./references#CD009258-bbs2-0021" title="The ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799‐803. ">Commission 1998</a>). </p> </section> </section> <section id="CD009258-sec-0037"> <h5 class="title">Secondary outcomes</h5> <section id="CD009258-sec-0038"> <h6 class="title">Short‐term effectiveness measure(s)</h6> <p> <ul id="CD009258-list-0004"> <li> <p>Seizure cessation within eight weeks of starting clobazam</p> </li> <li> <p>A decrease in seizure burden of 50% or more (50% responder rate) within eight weeks of starting clobazam </p> </li> </ul> </p> </section> <section id="CD009258-sec-0039"> <h6 class="title">Long‐term effectiveness measure(s)</h6> <p> <ul id="CD009258-list-0005"> <li> <p>The proportion of individuals who achieve six, 12 and 24 months' seizure freedom</p> </li> </ul> </p> </section> <section id="CD009258-sec-0040"> <h6 class="title">Tolerability measure(s)</h6> <p> <ul id="CD009258-list-0006"> <li> <p>Proportion of individuals experiencing adverse events requiring medication withdrawal</p> </li> <li> <p>Proportion of individuals experiencing any adverse events emerging during clobazam monotherapy (specific vigilance for sedation or drowsiness would be kept and data presented in each study would be summarized) </p> </li> </ul> </p> </section> <section id="CD009258-sec-0041"> <h6 class="title">Quality‐of‐life measure(s)</h6> <p> <ul id="CD009258-list-0007"> <li> <p>Quality‐of‐life outcomes measured on any validated scale (commonly used, validated, health‐related quality‐of‐life scales used in epilepsy include: Quality of Life in Childhood Epilepsy Questionnaire (QOLCE) and Quality of Life in Epilepsy Inventory‐89 and 31 (QOLIE‐89/31)) </p> </li> </ul> </p> </section> <section id="CD009258-sec-0042"> <h6 class="title">Tolerance measure(s)</h6> <p> <ul id="CD009258-list-0008"> <li> <p>Data on the development of anti‐seizure drug tolerance or tachyphylaxis using the study definitions </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD009258-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <p>We carried out a comprehensive search to identify all eligible trials regardless of language, year of publication, or status of publication (published in peer‐reviewed journal, conference proceedings, thesis, or unpublished). </p> <section id="CD009258-sec-0044"> <h4 class="title">Electronic searches</h4> <p>Searches were run for the original review in July 2011 and subsequent searches were run in March 2013, April 2015, January 2017, and March 2018. For the latest update we searched the following databases, with no language restrictions: </p> <p> <ul id="CD009258-list-0009"> <li> <p>Cochrane Register of Studies (CRS Web, 19 March 2018), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL) using the search strategy outlined in <a href="./appendices#CD009258-sec-0090">Appendix 1</a>. </p> </li> </ul> <ul id="CD009258-list-0010"> <li> <p>MEDLINE (Ovid, 1946 to 19 March 2018) using the search strategy set out in <a href="./appendices#CD009258-sec-0091">Appendix 2</a>. </p> </li> </ul> <ul id="CD009258-list-0011"> <li> <p>BIOSIS Previews (1969 to 19 March 2018) using the search strategy outlined in <a href="./appendices#CD009258-sec-0092">Appendix 3</a>. </p> </li> </ul> <ul id="CD009258-list-0012"> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (19 March 2018) using the search strategy shown in <a href="./appendices#CD009258-sec-0093">Appendix 4</a>. </p> </li> </ul> <ul id="CD009258-list-0013"> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">World Health Organization International Clinical Trials Registry Platform</a> (ICTRP, 19 March 2018) using the search strategy shown in <a href="./appendices#CD009258-sec-0094">Appendix 5</a>. </p> </li> </ul> </p> <p>Previously we also searched the Database of Abstracts of Reviews of Effectiveness (DARE) using the search strategy outlined in <a href="./appendices#CD009258-sec-0095">Appendix 6</a>, but this is now a closed archive, so it has not been searched again. </p> </section> <section id="CD009258-sec-0045"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of identified trials for additional reports of relevant studies. </p> </section> </section> <section id="CD009258-sec-0046"> <h3 class="title" id="CD009258-sec-0046">Data collection and analysis</h3> <section id="CD009258-sec-0047"> <h4 class="title">Selection of studies</h4> <p>Two authors (RA, VA) scanned the results of the search and performed a preliminary screen rejecting publications that were obviously unsuitable and retaining publications in which interventions seemed relevant. Two authors (VA, SK) independently inspected the remaining references that were not rejected and obtained the full text of all possibly relevant studies. Two authors independently applied inclusion and exclusion criteria, resolving disagreements by discussion. No doubts about any trial's eligibility were raised. We scrutinized the trial reports according to dates, location of the trial and interventions, to ensure that multiple publications from the same trial are included only once. We recorded potentially relevant references that were excluded along with the reason for their exclusion. </p> </section> <section id="CD009258-sec-0048"> <h4 class="title">Data extraction and management</h4> <p>For eligible studies, at least two of the authors (RA, VA, SK, NG) extracted the data using the pre‐designed agreed form, resolving discrepancies through discussion or by consulting the third author. We entered data into Review Manager software (<a href="./references#CD009258-bbs2-0036" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and checked them for accuracy. We ensured accuracy by comparing data extracted independently by two of the authors (RA, VA, SK, NG) and resolved any discrepancies by discussion or by consultation with the third author. </p> </section> <section id="CD009258-sec-0049"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (from RA, VA, SK, NG) independently assessed the methodological quality of each study and risk of bias using The Cochrane Collaboration’s 'Risk of bias' tool (<a href="./references#CD009258-bbs2-0029" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Cochrane Collaboration. ">Higgins 2011a</a>). Assessors were not blinded to the authors or source institution. The items included for appraisal were sequence generation for randomization, concealment of allocation, blinding, incomplete outcome data, selective outcome reporting and other potential sources of bias. Each of these factors was categorized as low risk, high risk or unclear risk with a brief overview (<a href="./appendices#CD009258-sec-0096">Appendix 7</a>). </p> </section> <section id="CD009258-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <p>We performed statistical analysis using RevMan 5 (<a href="./references#CD009258-bbs2-0036" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Since data for each outcome were available from any one study only, we could not perform meta‐analysis. </p> <section id="CD009258-sec-0051"> <h5 class="title">Dichotomous data</h5> <p>We calculated risk ratios (RRs) with 95% confidence intervals (CI) for dichotomous outcomes. </p> </section> <section id="CD009258-sec-0052"> <h5 class="title">Continuous data</h5> <p>For continuous variables, in future versions of the review, we will calculate difference in means or standardized mean differences (SMDs) along with 95% CIs. When two or more studies present their data derived from the same instrument of evaluation (with the same units of measurement), we will pool data as a mean difference (MD). Conversely, when primary studies express the same variables through different instruments (and different units of measurement) we will use the SMD. </p> </section> </section> <section id="CD009258-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>In future versions of the review, for missing data, we will attempt to contact the authors of original studies to obtain additional data. For all outcomes, we will carry out analyses on an intention‐to‐treat (ITT) basis as far as possible, that is, including all participants randomized in their original groups. </p> <p>For missing continuous data, we will estimate standard deviations (SDs) from other available data such as standard errors (SEs), or we will impute the data using methods suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009258-bbs2-0030" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). We will make no assumptions about loss to follow‐up for continuous data and we will base analyses on those individuals who completed the trial. We will perform ITT analyses where appropriate. We will perform a sensitivity analysis by calculating the treatment effect including and excluding the imputed data to see whether this would alter the outcome of the analysis. We will investigate the effect of drop‐outs and exclusions by conducting 'worst‐case' versus 'best‐case' scenario analyses. If there are any discrepancies in the number randomized and the number analyzed in each treatment group, we will calculate the percentage lost to follow‐up in each group and report the results. If drop‐outs exceed 10% for any trial, we shall assign the worse outcome to those lost to follow‐up for dichotomous outcomes and assess the impact of this in sensitivity analyses with the results of those completing the study. Where it is not possible to obtain missing data, we will record this in the data extraction form and report the information in the 'Risk of bias' table. For included studies, we will note levels of attrition. We will explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. </p> </section> <section id="CD009258-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>Although not relevant to the current version of the review, in future we will assess heterogeneity between pooled trials using the Chi² test in conjunction with the I² statistic (<a href="./references#CD009258-bbs2-0028" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>), which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (<a href="./references#CD009258-bbs2-0022" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We will consider a P value of less than 0.10 as statistically significant. If enough trials are identified, we will explore sources of heterogeneity using subgroup analyses. We will display results graphically using forest plots, and present a summary statistic if no major statistical heterogeneity (lack of overlap of confidence intervals on the forest plots) exists. We will consider values of I² of less than 25% to denote low heterogeneity, 50% or greater to be significant heterogeneity and 75% or greater to be substantial and major heterogeneity. </p> </section> <section id="CD009258-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>As sufficient trials become available in future, we will attempt to assess publication bias by preparing a funnel plot. We will then perform a visual assessment of funnel plot asymmetry. We will perform exploratory analyses to investigate any suggestion of visual asymmetry in the funnel plots. Our searches for trials listed in clinical trial registers and trial protocols should help to avoid publication bias and to assess outcome selection bias. Where necessary, we will contact study authors in an attempt to establish a full data set or obtain reasons for the non‐reporting of certain outcomes. </p> </section> <section id="CD009258-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We entered quantitative data into RevMan 5 and analyzed the data using Cochrane MetaView (<a href="./references#CD009258-bbs2-0036" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Pooled analyses were not feasible for the current version of the review. In future versions, we will use adjusted summary statistics if feasible, otherwise we will use unadjusted results. </p> <p> <ul id="CD009258-list-0014"> <li> <p>For time‐to‐event data, we will pool hazard ratios (HR) using the generic inverse variance facility of RevMan 5. </p> </li> <li> <p>For dichotomous outcomes, we will calculate and pool RRs for each study.</p> </li> <li> <p>For continuous outcomes, we will pool MDs between the treatment arms at the end of follow‐up if all trials measured the outcome on the same scale, otherwise we will pool SMDs, as discussed above. </p> </li> </ul> </p> <p>We will use a fixed‐effect meta‐analysis unless significant statistical or clinical heterogeneity are found, in which case we will use a random‐effects analysis if considered appropriate (<a href="./references#CD009258-bbs2-0023" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). If possible, we will synthesize studies making different comparisons using the methods described by <a href="./references#CD009258-bbs2-0019" title="BucherHC , GuyattGH , GriffithLE , WalterSD . The results of direct and indirect treatment comparisons in meta‐ analysis of randomised controlled trials. Journal of Clinical Epidemiology1997;50(6):683‐91. ">Bucher 1997</a>. </p> <p>We assessed the quality of the body of the evidence using the GRADE approach (<a href="./references#CD009258-bbs2-0029" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Cochrane Collaboration. ">Higgins 2011a</a>). Domains that determined the quality of the evidence were: </p> <p> <ul id="CD009258-list-0015"> <li> <p>study design;</p> </li> <li> <p>risk of bias;</p> </li> <li> <p>inconsistency of results;</p> </li> <li> <p>indirectness (non‐generalizability);</p> </li> <li> <p>imprecision (insufficient data);</p> </li> <li> <p>other factors (e.g. reporting bias).</p> </li> </ul> </p> <p>We reduced the quality of the evidence by one level for each of the domains that we encountered. We considered all plausible confounding factors and their effects as a reason to reduce any claimed effect and dose‐response gradient. We defined the following levels of evidence. </p> <p> <ul id="CD009258-list-0016"> <li> <p>High‐quality evidence: further research is very unlikely to change our confidence in the estimate of effect. There are consistent findings among 75% of RCTs with low risk of bias that are generalizable to the population in question. There are sufficient data, with narrow confidence intervals. There are no known or suspected reporting biases (all of the domains are met). </p> </li> <li> <p>Moderate‐quality evidence: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate (one of the domains is not met). </p> </li> <li> <p>Low‐quality evidence: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate (two of the domains are not met). </p> </li> <li> <p>Very low‐quality evidence: we are very uncertain about the estimate (three of the domains are not met). </p> </li> <li> <p>No evidence: no RCTs were identified that measured the outcome.</p> </li> </ul> </p> <p>We also considered a number of factors to place the results into a larger clinical context: temporality, plausibility, strength of association, adverse events, and costs. Not all of these were applicable for the current review, but are likely to be useful as more studies for clobazam monotherapy become available. </p> </section> <section id="CD009258-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Considerations of clinical diversity included assessment of differences in study location and setting, participant characteristics including co‐morbidities, characteristics of the trial interventions and of other care provided. </p> <p>We intended to analyze studies according to differences in the following pre‐planned subgroups. </p> <p> <ul id="CD009258-list-0017"> <li> <p>Age (children versus adults)</p> </li> <li> <p>Seizure semiology (focal with or without secondary generalization versus primary generalized)</p> </li> <li> <p>Seizure frequency prior to enrolment in the study</p> </li> <li> <p>Pre‐treatment electroencephalographic (EEG) findings</p> </li> <li> <p>Neuro‐imaging findings</p> </li> </ul> </p> <p>In the present version of review, sufficient data for sub‐group analyses were not available. </p> </section> <section id="CD009258-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>Where possible, we intended to perform sensitivity analyses to explore the effects of various aspects of trial and review methodology, including the effects of missing data and whether allocation was concealed. If sufficient data were available, we intended to conduct sensitivity analyses to determine the impact of excluding studies with lower methodological quality, for example: </p> <p> <ul id="CD009258-list-0018"> <li> <p>excluding trials at a high or unclear risk of bias;</p> </li> <li> <p>excluding unpublished studies, these may not have been subjected to the peer review process and may have intrinsic bias issues; </p> </li> <li> <p>excluding industry studies;</p> </li> <li> <p>excluding trials that have not assessed compliance.</p> </li> </ul> </p> <section id="CD009258-sec-0059"> <h5 class="title">'Summary of findings' tables</h5> <p>We used the principles of the GRADE approach to assess the quality of the body of evidence associated with specific outcomes and to construct 'Summary of findings' tables (SoF) (<a href="./references#CD009258-bbs2-0040" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chaper 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within‐study risk of bias (methodologic quality), the directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009258-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009258-sec-0060"></div> <section id="CD009258-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD009258-sec-0062"> <h4 class="title">Results of the search</h4> <p>We identified 291 publications by the search of electronic databases and trial registers. Because of duplication, we removed 89 articles. After review of 202 titles and abstracts by two authors (VA, RA), we considered that 17 studies were potentially eligible for inclusion, out of which 14 were excluded because either they used clobazam only for short‐term intermittent treatment for acute symptomatic seizures (<a href="./references#CD009258-bbs2-0004" title="BajajAS , BajajBK , PuriV , TayalG . Intermittent clobazam in febrile seizures: an Indian experience. Journal of Pediatric Neurology2005;3(1):19‐23. ">Bajaj 2005</a>; <a href="./references#CD009258-bbs2-0006" title="FeelyM , CalvertR , GibsonJ . Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. Lancet1982;2(8289):71‐3. [PUBMED: 6123810] ">Feely 1982a</a>; <a href="./references#CD009258-bbs2-0007" title="FeelyM , CalvertR , GibsonJ . Catamenial epilepsy as a model for testing a new anticonvulsant (clobazam). Irish Journal of Medical Science1982;151(11):358‐9. ">Feely 1982b</a>; <a href="./references#CD009258-bbs2-0008" title="FeelyM , CalvertR , GibsonJ . Clobazam in the treatment of catamenial epilepsy. British Journal of Clinical Pharmacology1982;13(2):273P‐4P. [Abstract: Proceedings of the British Pharmacological Society; 1981 Sept 16‐18; University of Oxford, Oxford, UK] ">Feely 1982c</a>; <a href="./references#CD009258-bbs2-0011" title="KhosroshahiN , FaramarziF , SalamatiP , HaghighiSM , KamraniK . Diazepam versus clobazam for intermittent prophylaxis of febrile seizures. Indian Journal of Pediatrics2011;78(1):38‐40. [PUBMED: 20890683] ">Khosroshahi 2011</a>; <a href="./references#CD009258-bbs2-0013" title="Ramachandran NairR , ParameswaranM , GirijaAS . Intermittent oral prophylaxis in preventing recurrent febrile seizures, diazepam versus clobazam: a randomised study in south Indian rural children. Epilepsia2005;46(Suppl 6):240. ">RamachandranNair 2005</a>; <a href="./references#CD009258-bbs2-0014" title="RoseW , KirubakaranC , ScottJX . Intermittent clobazam therapy in febrile seizures. Indian Journal of Pediatrics2005;72(1):31‐3. [PUBMED: 15684445] ">Rose 2005</a>), or they used clobazam as add‐on therapy instead of monotherapy (<a href="./references#CD009258-bbs2-0010" title="FigueroaD , AdlersteinL , ManterolaA . Clobazam in refractory epilepsies of children [Clobazam en epilepsias refractarias del nino]. Revista Chilena de Pediatria1984;55(6):401‐5. [PUBMED: 6399391] ">Figueroa 1984</a>; <a href="./references#CD009258-bbs2-0012" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. [PUBMED: 3115770] ">Koeppen 1987</a>; <a href="./references#CD009258-bbs2-0015" title="VajdaFJ , BladinPF , ParsonsBJ . Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy. Clinical and Experimental Neurology1985;21:177‐82. [PUBMED: 3843217] ">Vajda 1985</a>; <a href="./references#CD009258-bbs2-0016" title="YagiK , TakedaA , KawaiI . The clinical efficacy of nh‐15 (clobazam) for the treatment refractory epilepsy by the double‐blind comparative study with inactive placebo. Igakunoayumi1995;174(3):229‐41. ">Yagi 1995</a>; <a href="./references#CD009258-bbs2-0017" title="YamatogiY , OhtaharaS , ShigematsuH , OguniH , NakashimaM . Single blind comparative study of clobazam (NH‐15) with clonazepam in intractable childhood epilepsies. Journal of the Japan Epilepsy Society1997;15(2):110‐21. ">Yamatogi 1997</a>). One study (<a href="./references#CD009258-bbs2-0009" title="FeelyM , GibsonJ . Intermittent clobazam for catamenial epilepsy: tolerance avoided. Journal of Neurology, Neurosurgery, and Psychiatry1984;47(12):1279‐82. [PUBMED: 6392481] ">Feely 1984</a>), was found to be a case series, and was therefore excluded. Another study (<a href="./references#CD009258-bbs2-0005" title="BawdenHN , CamfieldCS , CamfieldPR , CunninghamC , DarwishH , DooleyJM , et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable; Canadian Study Group for Childhood Epilepsy. Epilepsy Research1999;33(2‐3):133‐43. [PUBMED: 10094425] ">Canadian Study Group 1999</a>), was part of a larger multi‐center study on the efficacy of clobazam and analyzed neuropsychological measures in children receiving clobazam verus those receiving standard monotherapy. However, those randomized to receive clobazam also included children who had previously been treated unsuccessfully with carbamazepine or one or more other AEDs. This study was therefore excluded (<a href="./references#CD009258-sec-0107" title="">Characteristics of excluded studies</a>). Three trials (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>; <a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a>; <a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a>), with 163 individuals randomized to clobazam monotherapy or other anti‐seizure medication (carbamazepine or phenytoin) monotherapy were analyzed (See <a href="#CD009258-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009258-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (results from updated searches)" data-id="CD009258-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (results from updated searches)</p> </div> </div> </div> </section> <section id="CD009258-sec-0063"> <h4 class="title">Included studies</h4> <p><a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> </p> <p>This single‐center, randomized open‐label study compared clobazam versus carbamazepine in children with benign childhood epilepsy with centrotemporal spikes (BCECTS). The outcome measures included the number of participants with more than 50% reduction in seizures, number of participants who were free of seizures in the last nine months, and the average time it took to achieve seizure freedom in participants treated with clobazam versus those treated with carbamazepine. This study also examined academic performance, behavior, adherence to treatment, parents’ degree of satisfaction and side effect profiles. </p> <p><a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a> </p> <p>This multi‐center study aimed to compare the effectiveness of clobazam, carbamazepine and phenytoin monotherapy in children with epilepsy. It had a randomized, double‐blind design with ITT analysis for the primary outcome measure of retention on the study medication for 12 months or discontinuation of the study medication for any reason, including adverse effects or inadequate seizure control. The study had three intervention arms: drug‐naive, previous failure with carbamazepine, and previous failure with other anti‐seizure medications. Only the first arm met the inclusion criteria for this review and was analyzed. This arm compared clobazam with standard treatment (carbamazepine) in drug‐naive participants with epilepsy, for a period of 12 months. </p> <p><a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a> </p> <p>This single‐center, randomized, open‐label study compared clobazam versus phenytoin in adolescents and adults with solitary neurocysticercosis granuloma. The primary outcome measure was number of treatment failures in each group due to breakthrough seizures or adverse events during the first six months after initiation. This study had some methodologic limitations as mentioned in <a href="#CD009258-sec-0065">Risk of bias in included studies</a>. </p> <p>The studies are summarized in <a href="./references#CD009258-sec-0106" title="">Characteristics of included studies</a>. </p> </section> <section id="CD009258-sec-0064"> <h4 class="title">Excluded studies</h4> <p>The reasons for exclusion are summarized in <a href="./references#CD009258-sec-0107" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD009258-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>Two of the included studies were adequately randomized, using either the permuted block technique (<a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a>), or a computer‐generated random number list (<a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a>). However, <a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> did not mention their method of random sequence generation. The review authors' judgements about the risks of bias are summarized in <a href="#CD009258-fig-0002">Figure 2</a> and <a href="#CD009258-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD009258-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD009258-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD009258-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009258-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD009258-sec-0066"> <h4 class="title">Allocation</h4> <p>The allocation sequence concealment is not described in any of the studies.</p> </section> <section id="CD009258-sec-0067"> <h4 class="title">Blinding</h4> <p>Two studies provided information on blinding. One of the included studies was double‐blind and used a 'double dummy' technique (<a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a>), but the other was an open‐label trial (<a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a>). The <a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a> had two outcome assessors, one of whom was blinded, whereas the blinding of the outcome assessor is not mentioned in <a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a>. This lack of blinding might have affected the assessment of subjective outcomes such as tolerability measures. <a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> did not provide details of blinding in outcome assessment. </p> </section> <section id="CD009258-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>The risk of attrition bias is assessed to be low, as all of the randomized participants were analyzed in all of the studies that is, the primary analysis was on an ITT basis. </p> </section> <section id="CD009258-sec-0069"> <h4 class="title">Selective reporting</h4> <p>We could not assess reporting bias as there were no pre‐published protocols available for any of the studies. </p> </section> <section id="CD009258-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>The <a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a> trial was funded by Hoechst‐Marion‐Roussel Canada, Inc, and the monitoring of data collection and entry was accomplished in this trial by Hoechst‐Marion‐Roussel Canada, Inc. <a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a> did not mention any sources of funding. However, this study initially estimated a sample size of 270 to detect a 10% difference in the primary outcome measure with a 90% confidence; but, they prematurely terminated the study with an actual sample of only 48 participants, due to relocation of a study investigator. Also in this study, outcome was assessed by the treating physician and a blinded research team member, but they do not mention how they reached a consensus in case of disagreement or discrepancy. Further, they do not report whether and how informed consent was obtained.<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> do not mention any funding source. No other sources of bias that could have affected the results were noted. </p> </section> </section> <section id="CD009258-sec-0071"> <h3 class="title" id="CD009258-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD009258-tbl-0001"><b>Summary of findings for the main comparison</b> Clobazam versus carbamazepine for focal or generalized seizures</a>; <a href="./full#CD009258-tbl-0002"><b>Summary of findings 2</b> Clobazam versus phenytoin for focal or generalized seizures</a> </p> <section id="CD009258-sec-0072"> <h4 class="title">Retention at 12 months</h4> <p>Data on 115 drug‐naive children were available for analysis of this outcome from one study only (<a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a>), in which 63 participants were randomized to clobazam and 52 to carbamazepine respectively. No statistically significant advantage of clobazam over carbamazepine was detected, with a risk ratio (RR) of 0.83, 95% CI (0.61 to 1.12) (<a href="./references#CD009258-fig-0007" title="">Analysis 1.1</a>; <a href="#CD009258-fig-0004">Figure 4</a>). No data were available for any subgroup analysis. </p> <div class="figure" id="CD009258-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 clobazam vs carbamazepine, outcome: 2.1 retention at 12 months" data-id="CD009258-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 clobazam vs carbamazepine, outcome: 2.1 retention at 12 months </p> </div> </div> </div> </section> <section id="CD009258-sec-0073"> <h4 class="title">Retention at six months</h4> <p>Data on 48 drug‐naive adolescents and adults with solitary cysticercus granuloma were available for analysis of this outcome from only one study (<a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a>). The number of participants randomized to clobazam and phenytoin arm were 21 and 27 respectively. Twenty out of 21 participants randomized to receive clobazam remained on the study medication for six months, compared to 18 out of 27 in the phenytoin group (RR 1.43, 95% CI 1.08 to 1.90) (<a href="./references#CD009258-fig-0014" title="">Analysis 2.1</a>; <a href="#CD009258-fig-0005">Figure 5</a>). No data were available for any subgroup analysis. </p> <div class="figure" id="CD009258-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 clobazam versus phenytoin, outcome: 1.1 retention at 6 months" data-id="CD009258-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 clobazam versus phenytoin, outcome: 1.1 retention at 6 months </p> </div> </div> </div> </section> <section id="CD009258-sec-0074"> <h4 class="title">Seizure freedom at specified time intervals</h4> <p>Data on 43 children were available for analysis of this outcome (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>). Participants with BCECTS were evaluated for seizure freedom at four weeks, between four and 40 weeks, and during the last nine months of treatment, and no statistically significant differences were identified between those allocated to receive clobazam versus carbamazepine. Eleven out of 18 participants randomized to receive clobazam were seizure free at four weeks, compared to 18/25 in the carbamazepine group (RR 0.85, 95% CI 0.55 to 1.32 <a href="./references#CD009258-fig-0008" title="">Analysis 1.2</a>). Thirteen out of 18 participants on clobazam were seizure free during the four to‐40‐week interval, compared to 19/25 in the carbamazepine group (RR 0.95, 95% CI 0.66 to 1.36 <a href="./references#CD009258-fig-0009" title="">Analysis 1.3</a>). Lastly, 15/18 participants in clobazam group were seizure free during the last nine months of therapy, compared to 17/25 in the carbamazepine group (RR 1.23, 95% CI 0.87 to 1.72 <a href="#CD009258-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD009258-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 clobazam versus carbamazepine, outcome: 1.4 terminal remission at 9 months (seizure free for last 9 months)" data-id="CD009258-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 clobazam versus carbamazepine, outcome: 1.4 terminal remission at 9 months (seizure free for last 9 months) </p> </div> </div> </div> </section> <section id="CD009258-sec-0075"> <h4 class="title">50% responder rate at four weeks</h4> <p><a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> provided data on 43 children regarding this outcome. There was no statistically significant difference in the proportion of children whose seizure frequency decreased by at least 50% (50% responder rate) at four weeks between the clobazam and carbamazepine groups (<a href="./references#CD009258-fig-0011" title="">Analysis 1.5</a>). Seventeen out of 18 participants randomized to receive clobazam achieved a 50% or greater reduction in seizures at four weeks, compared to 20/25 in the carbamazepine group (RR 1.18, 95% CI 0.94 to 1.48). </p> </section> <section id="CD009258-sec-0076"> <h4 class="title">Time to achieve seizure freedom</h4> <p>Data on 43 children were available for this outcome (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>). The mean time to achieve seizure freedom was 33.3 (± 45) days in participants randomized to clobazam (n = 18), compared to 48.2 (± 72.3) days in those allocated to receive carbamazepine (n = 25). </p> </section> <section id="CD009258-sec-0077"> <h4 class="title">Adverse effects</h4> <p>Data on adverse effects were provided by two studies.</p> <p>The first study compared clobazam with phenytoin in 48 adolescents and adults with symptomatic seizures due to solitary cysticercus granuloma (<a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a>). Overall, six out of 27 participants in the phenytoin group discontinued study medication during the study period after experiencing adverse effects, compared to none in the 21 participants in the clobazam group (RR 0.10, 95% CI 0.01 to 1.65) (<a href="./references#CD009258-fig-0016" title="">Analysis 2.3</a>; <a href="#CD009258-fig-0006">Figure 6</a>).The reported adverse effects included sedation, skin problems, allergic rash, tiredness, oral‐gingival problems, headache and weight gain (<a href="./references#CD009258-fig-0017" title="">Analysis 2.4</a>). The incidence of these adverse effects was not different between clobazam and phenytoin: sedation (RR 0.96, 95% CI 0.40 to 2.35), skin problems (RR 0.18, 95% CI 0.02 to 1.38), tiredness (RR 0.43, 95% CI 0.1 to 1.91), oral or gingival problems (RR 0.21, 95% CI 0.03 to 1.65), headache (RR 2.57, 95% CI 0.73 to 9.09) and weight gain (RR 11.45, 95% CI 0.65 to 201.6). </p> <p>The second study compared clobazam with carbamazepine in 43 children with BCECTS (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>). Overall, one participant out of 25 in the carbamazepine group discontinued the medication during the study period after experiencing adverse effects, compared to none in the 18 participants in the clobazam group. Reported adverse effects included vertigo, rash, headaches, somnolence/sedation, nausea/vomiting, diarrhea, tremors, and fatigue. The number of participants reporting adverse effects were not different between the clobazam and carbamazepine groups (RR 0.52, 95% CI 0.16 to 1.70, P = 0.26, <a href="./references#CD009258-fig-0012" title="">Analysis 1.6</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009258-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009258-sec-0078"></div> <section id="CD009258-sec-0079"> <h3 class="title" id="CD009258-sec-0079">Summary of main results</h3> <p>Three studies with a total of 206 participants met the inclusion criteria for this review (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>; <a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a>; <a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a>). Two of the included trials were adequately randomized, and overall, we judged them to be of low quality (<a href="#CD009258-fig-0003">Figure 3</a>). None of the studies provided data for our primary outcome of time on allocated treatment, a clinically meaningful measure combining both efficacy and tolerability. No statistically significant advantage of clobazam over carbamazepine was detected in 115 participants in the <a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a> trial (RR 0.83, 95% CI 0.61 to 1.12) for retention at 12 months. However, a slight advantage for clobazam over phenytoin (RR 1.43, 95% CI 1.08 to 1.90) was seen in 48 participants with single cysticercus granuloma in the brain for retention at six months (<a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a>). </p> <p>No significant differences were identified between clobazam and carbamazepine for seizure freedom at four weeks (RR 0.85, 95% CI 0.55 to 1.32), between four and 40 weeks (RR 0.95, 95% CI 0.66 to 1.36), and during the last nine months of treatment (RR 1.23, 95% CI 0.87 to 1.72). Also, no significant differences were noted for clobazam versus carbamazepine in 43 participants with BCECTS in the 50% responder rate (RR 1.18, 95% CI 0.94 to 1.48) at four weeks (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>). However, participants randomized to clobazam achieved seizure control sooner than those treated with carbamazepine (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>). </p> <p>In one of the studies, people receiving clobazam were found to be less likely to discontinue it due to adverse effects compared to phenytoin (RR 0.10, 95% CI 0.01 to 1.65, <a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a>). However, the wide confidence interval and potential for bias in the one open‐label study where this outcome could be analyzed, compromise the clinical relevance of this result. </p> <p>In another study, no difference in the number of participants reporting adverse effects with clobazam or carbamazepine was noted, and the proportion of participants discontinuing treatment due to adverse effects was minimal and comparable between the two groups (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>). </p> </section> <section id="CD009258-sec-0080"> <h3 class="title" id="CD009258-sec-0080">Overall completeness and applicability of evidence</h3> <p>An extensive, structured search found three trials fulfilling the inclusion criteria for this review. Overall, the result of this systematic review finds no evidence for the superiority of clobazam monotherapy compared to adequate comparator monotherapy for retention at 12 months, and only slight advantage for retention at six months, and time to achieve seizure freedom, in people with focal or generalized seizures. The analyzed outcomes were based on results from a single study in each case. In the absence of individual participant data, pooled analysis was not possible for the six months' retention outcome. The clinical applicability for 12 months' retention is limited by lack of data for focal versus generalized seizures, an important decision‐making factor in clinical practice. Similarly, the generalizability for six months' retention is not possible, due to a modest effect size and selected population consisting only of participants with solitary brain cysticercus granuloma.The modest advantage seen regarding time to achieve seizure freedom is also difficult to interpret, as far as clinical applicability and generalizability is concerned. This outcome was reported in only participants with BCECTS, and was not substantiated by sustaining seizure freedom over time, which is more important in clinical practice. </p> </section> <section id="CD009258-sec-0081"> <h3 class="title" id="CD009258-sec-0081">Quality of the evidence</h3> <p>The quality of evidence is low due to actual or possible biases in the included studies. None of the studies have described allocation concealment. The <a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a> trial was funded by a pharmaceutical company, which also monitored data collection and entry. The <a href="./references#CD009258-bbs2-0003" title="KaushalS , RaniA , ChopraSC , SinghG . Safety and efficacy of clobazam versus phenytoin‐sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurology India2006;54(2):157‐60. [PUBMED: 16804259] ">Kaushal 2006</a> study was open‐label and certain issues were not addressed including informed consent, resolution of conflict in case of disagreement between two outcome assessors and discrepancy between CONSORT flow diagram and text/table regarding numbers randomized to each arm. The author having access to the study data did not reply, although the corresponding author had promised to do so. The <a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> study was also open‐label, and did not provide information about randomization and allocation concealment. </p> </section> <section id="CD009258-sec-0082"> <h3 class="title" id="CD009258-sec-0082">Potential biases in the review process</h3> <p>The eligibility for inclusion, data extraction and 'Risk of bias' assessment was carried out by two authors (VA and RA) independently, thereby reducing the chances of bias. No major potential biases in the review process are highlighted. </p> </section> <section id="CD009258-sec-0083"> <h3 class="title" id="CD009258-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>There are no other systematic reviews analyzing clobazam monotherapy in focal or generalized seizures. However, the International League Against Epilepsy (ILAE) guideline for anti‐epileptic drug monotherapy (<a href="./references#CD009258-bbs2-0026" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , ChadwickD , GuerreiroC , et al. ILAE Treatment Guidelines: Evidence‐based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2006;47(7):1094‐120. ">Glauser 2006</a>), included the <a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a> trial and categorized it as a class III study based on their criteria. Since the ILAE guideline analyzed outcomes based on participants' age and seizure type, the <a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a> trial was considered uninformative as it fails to provide outcome data separately for focal and generalized seizures. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009258-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (results from updated searches)" data-id="CD009258-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (results from updated searches)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD009258-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009258-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 clobazam vs carbamazepine, outcome: 2.1 retention at 12 months" data-id="CD009258-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 clobazam vs carbamazepine, outcome: 2.1 retention at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 clobazam versus phenytoin, outcome: 1.1 retention at 6 months" data-id="CD009258-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 clobazam versus phenytoin, outcome: 1.1 retention at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 clobazam versus carbamazepine, outcome: 1.4 terminal remission at 9 months (seizure free for last 9 months)" data-id="CD009258-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 clobazam versus carbamazepine, outcome: 1.4 terminal remission at 9 months (seizure free for last 9 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus carbamazepine, Outcome 1 Retention at 12 months." data-id="CD009258-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus carbamazepine, Outcome 1 Retention at 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus carbamazepine, Outcome 2 Seizure freedom at 4 weeks." data-id="CD009258-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus carbamazepine, Outcome 2 Seizure freedom at 4 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus carbamazepine, Outcome 3 Seizure freedom between weeks 4 and 40." data-id="CD009258-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus carbamazepine, Outcome 3 Seizure freedom between weeks 4 and 40. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus carbamazepine, Outcome 4 Terminal remission at 9 months (seizure free for last 9 months)." data-id="CD009258-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus carbamazepine, Outcome 4 Terminal remission at 9 months (seizure free for last 9 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus carbamazepine, Outcome 5 50% responder rate at 4 weeks." data-id="CD009258-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus carbamazepine, Outcome 5 50% responder rate at 4 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus carbamazepine, Outcome 6 Reported adverse effects (number of participants)." data-id="CD009258-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus carbamazepine, Outcome 6 Reported adverse effects (number of participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus carbamazepine, Outcome 7 Discontinued study medication due to adverse effects (number of participants)." data-id="CD009258-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus carbamazepine, Outcome 7 Discontinued study medication due to adverse effects (number of participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Clobazam versus phenytoin, Outcome 1 Retention at 6 months." data-id="CD009258-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Clobazam versus phenytoin, Outcome 1 Retention at 6 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Clobazam versus phenytoin, Outcome 2 Breakthrough seizure(s) during study period." data-id="CD009258-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Clobazam versus phenytoin, Outcome 2 Breakthrough seizure(s) during study period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Clobazam versus phenytoin, Outcome 3 Discontinued study medication due to adverse effects." data-id="CD009258-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Clobazam versus phenytoin, Outcome 3 Discontinued study medication due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009258-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/urn:x-wiley:14651858:media:CD009258:CD009258-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_t/tCD009258-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Clobazam versus phenytoin, Outcome 4 Reported adverse effects." data-id="CD009258-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Clobazam versus phenytoin, Outcome 4 Reported adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/media/CDSR/CD009258/image_n/nCD009258-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009258-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Clobazam versus carbamazepine for focal or generalized seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clobazam versus carbamazepine for focal or generalized seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with focal or generalized seizures<br/> <b>Settings:</b> 15 Canadian pediatric epilepsy centers (<a href="./references#CD009258-bbs2-0002" title="Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia1998;39(9):952‐9. [PUBMED: 9738674] ">Canadian Study Group 1998</a>); single center, outpatient clinic from Cuba (<a href="./references#CD009258-bbs2-0001" title="AndradeR , García‐EspinosaA , Machado‐RojasA , García‐GonzálezME , Trápaga‐QuincosesO , Morales‐ChacónLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia Rolándica]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>)<br/> <b>Intervention:</b> clobazam versus carbamazepine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Clobazam </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time on allocated treatment (retention time)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Retention at 12 months</b><br/> Follow‐up: mean 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.83</b> (0.61 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>115<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>543 per 1000</b> (399 to 732) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure freedom at 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>720 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>611 per 1000</b> (396 to 950) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.85</b> (0.55 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>low</b><sup>2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure freedom 4‐40 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>760 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>722 per 1000</b> (502 to 1034) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.95</b> (0.66 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>low</b><sup>2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50% responder rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>944 per 1000</b> (752 to 1184) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.18</b> (0.94 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>low</b><sup>2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects requiring withdrawal/discontinuation of study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Blinding of participants and personnel was not done in this open‐label study. This can potentially affect assessment of this outcome. Downgraded by 1.<br/> <sup>2</sup>Only 1 study, hence no 'inconsistency' and no 'publication bias'.<br/> <sup>3</sup>Wide CI, downgraded by 1. </p> <p><sup>4</sup>Allocation concealment not stated, which could potentially introduce selection bias. Blinding of participants and personnel was not done in this open‐label study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Clobazam versus carbamazepine for focal or generalized seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009258-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Clobazam versus phenytoin for focal or generalized seizures</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clobazam versus phenytoin for focal or generalized seizures</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma </p> <p><b>Settings:</b> single Indian teaching hospital </p> <p><b>Intervention:</b> clobazam </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Clobazam versus phenytoin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time on allocated treatment (retention time)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Retention at 6 months</b> (measured by the number of treatment failures in each group, which was defined as either breakthrough seizure or adverse effects requiring discontinuation or dose modification of study medication)<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>RR 1.43</b> <br/> (1.08 to 1.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>48<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>953 per 1000</b> (720 to 1267) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure freedom at 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure freedom 4‐40 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50% responder rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects requiring withdrawal/discontinuation of study medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.10</b> <br/> (0.01 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>48<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/> (2 to 367) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Allocation concealment not stated, which could potentially introduce selection bias. Blinding of participants and personnel was not done in this open‐label study. This can potentially affect assessment of 'adverse effects requiring withdrawal' and hence 'retention time'. Downgraded by 1.<br/> <sup>2</sup>Only 1 study, thus no 'inconsistency' and no 'publication bias'.<br/> <sup>3</sup>Wide confidence interval and small sample size. Downgraded by 1. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Clobazam versus phenytoin for focal or generalized seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/full#CD009258-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009258-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Clobazam versus carbamazepine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Retention at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.61, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seizure freedom at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.55, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Seizure freedom between weeks 4 and 40 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.66, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Terminal remission at 9 months (seizure free for last 9 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.87, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 50% responder rate at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.94, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Reported adverse effects (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.16, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Discontinued study medication due to adverse effects (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.02, 10.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Clobazam versus carbamazepine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009258-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Clobazam versus phenytoin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Retention at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.08, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Breakthrough seizure(s) during study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.05, 3.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Discontinued study medication due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Reported adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.32, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.40, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Skin problems including allergic rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Tiredness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.10, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Oral or gingival problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.03, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.73, 9.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.45 [0.65, 201.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Clobazam versus phenytoin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009258.pub3/references#CD009258-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009258.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009258-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009258-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD009258-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009258-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009258\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009258\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009258\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009258\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009258\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009258.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009258.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009258.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009258.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009258.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716822484"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009258.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716822488"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009258.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da8e2cea81be3',t:'MTc0MDcxNjgyMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 